Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | AMD1 | P17707 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.33 |
| ▸ | NADK | O95544 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17612669 | 0.88 | ADK (0.65) | ADKADORA1ADORA3ADORA2AHSPA5 | |
| SCHEMBL17612652 | 0.88 | ADK (0.65) | ADKADORA1ADORA3ADORA2AHSPA5 | |
| SCHEMBL17612673 | 0.88 | ADK (0.65) | ADKADORA1ADORA3ADORA2AHSPA5 | |
| SCHEMBL17612666 | 0.88 | ADK (0.53) | ADKADORA1AMD1 | |
| SCHEMBL17612655 | 0.82 | ADK (0.53) | ADKADORA1ADORA3ADORA2AHSPA5 | |
| SCHEMBL17612654 | 0.82 | ADK (0.53) | ADKADORA1ADORA3ADORA2AHSPA5 | |
| SCHEMBL17612653 | 0.81 | ADK (0.44) | ADKHSPA8 | |
| SCHEMBL17612661 | 0.81 | AHCY (0.49) | ADKNADKAHCY | |
| SCHEMBL17612662 | 0.80 | FBP1 (0.50) | ADKADORA1 | |
| SCHEMBL17612664 | 0.80 | ADK (0.53) | ADKADORA1ADORA3ADORA2AHSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | ADK 3595/4885ADORA1 4716/4885ADORA3 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.